Navigation Links
Concord Grape Juice Has No Significant Impact on Body Weight
Date:10/6/2008

Recent study revealed that drinking polyphenol-rich 100% Concord grape juice was not associated with changes in appetite, energy intake or body weight

CONCORD, Mass., Oct. 6 /PRNewswire/ -- Regular consumption of 100% polyphenol-rich Concord grape juice did not cause significant weight gain, was not associated with changes in appetite and was shown to reduce waist circumference according to new data presented at the 49th Annual Meeting of the American College of Nutrition in Arlington, Virginia(i).

The 12 week, double-blind, placebo-controlled trial examined the effect of regular consumption of 100% Concord grape juice on body weight, diet quality, and markers of metabolic syndrome. The study included 76 men and women between the ages of 18 and 50 years who were slightly overweight (body mass index of 25.0 to 29.9). Each participant drank two 8-ounce servings of 100% Concord grape juice per day (n=25), a polyphenol-free grape-flavored drink (n=26) or was assigned to a non-treatment control group (n=25). The two test beverages were calorie and sugar matched but only the 100% Concord grape juice contained natural polyphenolic compounds(i).

Participants in the polyphenol-rich 100% Concord grape juice arm did not show significant weight gain whereas participants who drank the placebo gained on average 1.6kg / 3.4lbs (p<0.05) compared to baseline. Those in the 100% Concord grape juice arm did not show a significant change in appetite, while those who drank the placebo showed a significant decline in self-reported fullness (p<0.005) over the same time period. Furthermore, participants in the 100% Concord grape juice arm exhibited a significant reduction in waist circumference, demonstrating a beneficial effect on one of the markers of metabolic syndrome. There were no changes in other markers of metabolic syndrome, including cholesterol, triglyceride, and fasting glucose levels which were all within normal limits throughout the study.

"P
'/>"/>

SOURCE Welch's
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
3. Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail
4. Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
5. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
6. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
7. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
8. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
9. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
10. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- , Revenues from continuing operations of $1.9 ... EPS from continuing operations of $1.08, up 1.9% versus  prior ... $0.92, 7% below prior year , Cash from operations ... Full year 2014 revenues now expected to be up 2.5% ... Full year 2014 adjusted diluted EPS range narrowed to  $4.00 ...
(Date:7/24/2014)... July 24, 2014 HIGHLIGHTS:Q2 2014 Results ... , Reported sales increased 3% to $701 million.  Sales ... rates added one percentage point to sales growth. , ... 6% in Applied and 1% in SAFC Commercial. , ... 2013, an increase of 13%.  Adjusted diluted EPS in Q2 ...
(Date:7/24/2014)... --  ndd Medical Technologies , a leader in innovative ... announced that its EasyOne Pro ® has been ... Capacity (DLCO) for phase 2 of the COPDGene ® ... Pulmonary Disease (COPD) ever undertaken.  COPD is now the ... affects millions of people worldwide.  In ...
Breaking Medicine Technology:Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15
... and Company (NYSE: LLY ) announced that ... Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution ... study objective to restore testosterone levels to the normal ... testosterone. In addition, secondary outcomes showed that the treatment ...
... Wis., June 28, 2011 Novelos Therapeutics, Inc. ... for treatment and diagnosis of cancer, today announced that ... the defendants, motion to dismiss the putative federal securities ... Court for the District of Massachusetts in March 2010 ...
Cached Medicine Technology:Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 2Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 3Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 4Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 5Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 6Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 2Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 3
(Date:7/24/2014)... 24, 2014 The Biofeedback ... a new distribution agreement with game development company ... the two groups to offer Zukor's Grind ... biofeedback and neurofeedback in European and international markets. ... developed expressly to be used as a biofeedback/neurofeedback ...
(Date:7/24/2014)... July 24, 2014 The North American air ... billion in 2014, and is expected to register a CAGR ... has been the biggest market for the air and missile ... U.S. market has witnessed budget cuts as well. , Browse ... defense radar market report, to get an idea of the ...
(Date:7/24/2014)... Steven Reinberg HealthDay ... Children covered by Medicaid, the publicly funded insurance program for ... more often than uninsured or privately insured youngsters, a U.S. ... than those with private insurance to visit for a reason ... survey conducted by the U.S. Centers for Disease Control and ...
(Date:7/24/2014)... News) -- Even though its use is often advised by ... does not help treat lower back pain, according to a ... was no more effective than a dummy pill for more ... Besides showing no effect in easing discomfort, the study also ... tied to back pain, nor did it improve patients, overall ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 While healthcare ... in providing quality interpretation services to non-English speakers within ... down. According to Common Sense Advisory, the language ... to $2.3 billion in 2016 (1); additionally, officials at ... to shift over to video remote interpreting ...
Breaking Medicine News(10 mins):Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 2Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 3Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 2Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 3Health News:Stratus Video Interpreting Predicts $1 Billion Market Shift to Video Remote Interpreting by 2016 as Court and Healthcare Systems Heed Cost-Effectiveness 4
... Supported Efficacy, Safety and Tolerability of ... with Schizophrenia -, TOKYO and PRINCETON, N.J., ... Squibb Company (NYSE: BMY ) announced today ... the supplemental New,Drug Application for the atypical antipsychotic ...
... be lifesavers, study suggsts , TUESDAY, Nov. 6 (HealthDay ... artery bypass graft (CABG) surgery reduces a patient,s risk ... the Cleveland Clinic, included more than 5,200 patients who ... overall incidence of post-operative stroke one year after surgery ...
... To help raise awareness about the,prevalence of ... serving our country, TriWest Healthcare Alliance has contributed,$50,000 ... TBI. "According to the Department of Defense, ... members sustaining injuries in the Global War,on Terror ...
... Focus on Growth Businesses, LEHIGH VALLEY, Pa., Nov. ... Chemie AG are in advanced discussions over Wacker,s,purchase of ... Systems (WPS) and Air Products Polymers (APP), including APP,s,vinyl ... and,Wacker 35 percent. As for WPS, Wacker owns 80 ...
... 7 The Disabled American,Veterans (DAV) is commending ... the largest increase in funding for the Department ... on Congress and the,Administration to support this important ... Military Construction and Veterans Affairs Appropriations bill,calls for ...
... QED International Associates Inc.,administrator for the HealthShares(TM) ... today announced that effective at the,opening of trading ... GIVN ) will replace Dade Behring Holdings, ... Index, and Inverness Medical Innovations,(Amex: IMA ) ...
Cached Medicine News:Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 2Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 3Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 4Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 5Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 6Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 7Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 8Health News:TriWest Contributes $50,000 to Bob Woodruff Family Fund for Traumatic Brain Injury 2Health News:Air Products in Advanced Discussions With Wacker Over Polymers Business 2Health News:VA Budget Earns High Praise 2Health News:QED International Associates Announces Changes to the HealthShares(TM) Composite, and the HealthShares(TM) Diagnostics Indexes 2
This kit has been designed for the quantitative,determination of total immunoreactive intact PTH (Total,Intact PTH) in blood samples. The Total Intact PTH,level is the sum of PTH (1-84) and N-t...
Fully automated immunochemiluminometric assay for the rapid intraoperative,measurement of Intact PTH 1-84 using human serum or EDTA plasma....
... exclusively distributed by Medtronic, sets the ... intra-operative imaging with surgical navigation in ... is one of the most comprehensive ... Exceptional image quality from a low-field ...
... nm and 940 nm) laser system is ... solid-state laser quickly and effectively treats vascular ... offers the clinical versatility to precisely target ... vessels in a convenient, affordable package. , ...
Medicine Products: